Cholesterol is eliminated from neurons by oxidization, which generates oxysterols. Cholesterol oxidation is mediated by the enzymes cholesterol 24-hydroxylase (CYP46A1) and cholesterol 27-hydroxylase (CYP27A1). Immunocytochemical studies show that CYP46A1 and CYP27A1 are expressed in neurons and some astrocytes in the normal brain, and CYP27A1 is present in oligodendrocytes. In Alzheimer's disease (AD), CYP46A1 shows prominent expression in astrocytes and around amyloid plaques, whereas CYP27A1 expression decreases in neurons and is not apparent around amyloid plaques but increases in oligodendrocytes. Although previous studies have examined the effects of synthetic oxysterols on the processing of amyloid precursor protein (APP), the actions of the naturally occurring oxysterols have yet to be examined. To understand the role of cholesterol oxidation in AD, we compared the effects of 24(S)-and 27-hydroxycholesterol on the processing of APP and analyzed the cell-specific expression patterns of the two cholesterol hydroxylases in the human brain. Both oxysterols inhibited production of A␤ in neurons, but 24(S)-hydroxycholesterol was ϳ1000-fold more potent than 27-hydroxycholesterol. The IC 50 of 24(S)-hydroxycholesterol for inhibiting A␤ secretion was ϳ1 nM. Both oxysterols induced ABCA1 expression with IC 50 values similar to that for inhibition of A␤ secretion, suggesting the involvement of liver X receptor. Oxysterols also inhibited protein kinase C activity and APP secretion following stimulation of protein kinase C. The selective expression of CYP46A1 around neuritic plaques and the potent inhibition of APP processing in neurons by 24(S)-hydroxycholesterol suggests that CYP46A1 affects the pathophysiology of AD and provides insight into how polymorphisms in the CYP46A1 gene might influence the pathophysiology of this prevalent disease.
Cholesterol is eliminated from neurons by oxidization, which generates oxysterols. Cholesterol oxidation is mediated by the enzymes cholesterol 24-hydroxylase (CYP46A1) and cholesterol 27-hydroxylase (CYP27A1).
Immunocytochemical studies show that CYP46A1 and CYP27A1 are expressed in neurons and some astrocytes in the normal brain, and CYP27A1 is present in oligodendrocytes. In Alzheimer's disease (AD), CYP46A1 shows prominent expression in astrocytes and around amyloid plaques, whereas CYP27A1 expression decreases in neurons and is not apparent around amyloid plaques but increases in oligodendrocytes. Although previous studies have examined the effects of synthetic oxysterols on the processing of amyloid precursor protein (APP), the actions of the naturally occurring oxysterols have yet to be examined. To understand the role of cholesterol oxidation in AD, we compared the effects of 24(S)-and 27-hydroxycholesterol on the processing of APP and analyzed the cell-specific expression patterns of the two cholesterol hydroxylases in the human brain. Both oxysterols inhibited production of A␤ in neurons, but 24(S)-hydroxycholesterol was ϳ1000-fold more potent than 27-hydroxycholesterol. The IC 50 of 24(S)-hydroxycholesterol for inhibiting A␤ secretion was ϳ1 nM. Both oxysterols induced ABCA1 expression with IC 50 values similar to that for inhibition of A␤ secretion, suggesting the involvement of liver X receptor. Oxysterols also inhibited protein kinase C activity and APP secretion following stimulation of protein kinase C. The selective expression of CYP46A1 around neuritic plaques and the potent inhibition of APP processing in neurons by 24(S)-hydroxycholesterol suggests that CYP46A1 affects the pathophysiology of AD and provides insight into how polymorphisms in the CYP46A1 gene might influence the pathophysiology of this prevalent disease.
Alzheimer's disease (AD)
1 is characterized by a widespread loss of neurons and an even greater loss of synapses (1) . The neurodegeneration that occurs in AD is associated with restructuring of the neuropil. Degenerating neurons retract their processes and reduce the number of synapses (1) . Neurons with reduced arborization have less surface area and correspondingly less plasma membrane. Cholesterol is the major sterol present in the plasma membrane. Because cholesterol is so abundant, the synaptic degeneration occurring in AD requires that neuron dispose of the excess cholesterol.
Cholesterol is catabolized through three main routes. Cholesterol can be esterified and stored within neurons as cholesterol esters (2) . Alternatively, cholesterol can be oxidized at the 24 or 27 position to form 24(S)-hydroxycholesterol (24-OHC) or 27-hydroxycholesterol (27-OHC), which are termed oxysterols (2, 3) . Both oxysterols are more soluble than cholesterol and are excreted from cells to associate with lipoprotein particles in serum or extracellular fluid. Oxysterols serve a dual function because they are both cholesterol catabolites and ligands of the nuclear transcription factor LXR (4). The oxysterols are particularly intriguing because cholesterol 24-hydroxylase (CYP46A1), one of the enzymes that oxidizes cholesterol, is largely brainspecific, whereas the other enzyme, cholesterol 27-hydroxylase (CYP27A1), is expressed more broadly (5) .
Multiple studies indicate that levels of 24-OHC increase in plasma of patients with neurodegenerative illness, including AD (6 -8); however, it is unclear whether increases in 24-OHC affect the pathophysiology or modulate APP metabolism. Recent studies show that the processing of APP is sensitive to cholesterol levels. Cleavage of APP by ␤-and ␥-secretases produces A␤. These cleavage events take place in the high cholesterol environments of lipid raft domains. Reducing cholesterol levels inhibits A␤ production and increases secretion of APP (9 -11) . The dependence of A␤ production on cholesterol has generally been explained by localization of ␤-and ␥-secretases to lipid rafts (12) (13) (14) (15) . The relationship between A␤ and cholesterol has led to speculation that statins, a type of medicine that lowers cholesterol, might reduce A␤ production and be useful as a therapeutic agent for AD (16, 17) . Cholesterol catabolites also modulate A␤ production. Cholesterol esters increase A␤ production, and inhibiting the enzyme acyl-coenzyme A:choles-terol acyltransferase that synthesizes these enzymes reduces A␤ production (18) . In contrast, recent studies show that the synthetic oxysterol 22-hydroxycholesterol inhibits A␤ production in some neuroblastoma cell lines (19, 20) . Understanding how production of 24(S)-hydroxycholesterol affects APP metabolism has taken on particular relevance because of two reports suggesting that polymorphisms in CYP46A1 are associated with an increased load of A␤ or earlier onset of AD (21, 22) .
In the present study we compared the expression of CYP24 with CYP27A1 in the brains of patients with AD and agematched controls. We also examined how the oxysterol products of these two enzymes, 24-OHC and 27-OHC, affect APP processing in primary neurons. We observed that the distribution of both enzymes change in the brains of subjects with AD. CYP46A1 is selectively expressed in degenerating neurites around senile plaques, whereas CYP27A1 expression is increased in white matter oligodendrocytes. We showed that 24-and 27-OHC inhibit A␤ production and protein kinase C (PKC)-stimulated APP secretion, but 24-OHC is more potent that 27-OHC. Inhibition of APP secretion can be explained by indirect inhibition of PKC activity in neurons, which suggests a role for 24-OHC in signal transduction.
MATERIALS AND METHODS
Tissue-Cortical tissue (fixed and frozen) was obtained from seven subjects with AD (mean age 77.0 Ϯ 2.2 years, mean post-mortem interval 16.9 Ϯ 6.0 h) and seven normal subjects (mean age 73.3 Ϯ 3.1 years, mean post-mortem interval 6.3 Ϯ 2.4 h). The tissue was obtained from the Loyola University Medical Center Brain Bank. All AD subjects had moderate to severe dementia.
Primary Cortical Neurons-Neurons were obtained from SpragueDawley rat pups (E18), cultured on poly-L-lysine-coated 75-cm 2 flasks using 9 million cells/flask, and plated with neurobasal medium with B27 supplement (Invitrogen), which contains retinoic acid. At day 3, the neurons were treated with 50 M araC. After 24 h the medium was removed, and fresh medium containing neurobasal, B27 supplement, and 10% fetal bovine serum was added. Six days after plating, the cells were treated with APP adenovirus (multiplicity of infection ϭ 10) for 6 h (23). The next day, cells were treated with an oxysterol in fresh medium consisting of neurobasal, B27 supplement, and 10% fetal bovine serum for 24 h. Medium was collected for measuring A␤. The cells were then incubated in fresh serum-free neurobasal/B27 medium containing oxysterol. After 1 h, the medium was replaced with fresh serum-free neurobasal/B27 medium containing oxysterol for 1 h, and the medium from this second incubation was collected to measure basal APP secretion. The neurons were then incubated in fresh serum-free neurobasal/ B27 medium containing oxysterol with and without 1 M phorbol 12-myristate 13-acetate (PMA) for 1 h, and the medium was again collected. Secreted APP was concentrated from the medium samples by heparin-agarose immunoprecipitation, and APP was analyzed by immunoblot (24) . Cells were collected, APP in the lysates was analyzed by immunoblot, and PKC was assayed as described below. For analysis of ABCA1, the neurons were lysed in buffer containing 250 mM sucrose, 10 mM HEPES (pH 7.4), plus protease inhibitors. After quantification of protein by BCA assay, the lysates were incubated in SDS loading buffer for 30 min, separated by electrophoresis on a SDS-6% polyacrylamide gel, and then immunoblotted (25) .
Adenoviral Treatment-Adenoviral expression of APP was achieved by infecting neurons at a multiplicity of infection of 10 as described previously (23) .
Antibodies-Antibodies 3046 and 3047 were rabbit polyclonal antibodies produced against amino acids 226 -242 of human CYP46A1. The third CYP46A1 antibody, T623, was produced against amino acids 254 -270 of murine Cyp46A1 and has been described previously (5) . Anti-CYP27A1 antibody recognizes amino acids 15-28 of mature CYP27A1 and is similar to one described previously by Cali and Russell (26) . LN27, a monoclonal antibody directed against the N terminus of APP, was used to detect APPs (Zymed Laboratories Inc.). Holo-APP and C-terminal fragments were detected using antibody 0443, as described previously (27) . ABCA1 was detected with rabbit anti-ABCA1 (1:1000, Novus).
Immunocytochemistry-Free-floating fixed 40-m tissue sections were used for immunocytochemistry. The samples were washed, permeabilized by incubation for 30 min with 0.2% Triton X-100, blocked with 5% dry milk, 1% goat serum, and phosphate-buffered saline, washed, incubated overnight in primary antibody in 2% bovine serum albumin, 0.1% Triton X-100, and phosphate-buffered saline, washed, incubated for 3 h in secondary antibody in 2% bovine serum albumin, 0.1% Triton X-100, and phosphate-buffered saline, washed, and then cover-slipped.
Immunoblotting-Transfers to polyvinylidene difluoride (Bio-Rad) were carried out overnight at 4°C at 0.05 amps/gel in transfer buffer. The immunoblot was blocked in 0.2% I-block (Tropix) in Tris-buffered saline with 0.1% Tween 20 for 1 h at room temperature with shaking. We then incubated blots overnight at 4°C in primary antibody at appropriate the concentration in 5% bovine serum albumin in Trisbuffered saline with Tween 20. Blots were then washed three times for 10 min each and incubated for 3 h in secondary antibody (1:5000, Jackson Laboratories) in I-block at room temperature. Blots were washed three times and developed using a chemiluminescent reaction (PerkinElmer Life Sciences).
Thioflavine T Staining-Following the immunocytochemical treatment, sections were incubated with 0.5% thioflavine T for 8 min, washed three times in 80% ethanol, washed once in H 2 O, and then mounted.
A␤ Enzyme-linked Immunosorbent Assays-Secreted A␤40 and A␤42 levels were analyzed by sandwich enzyme-linked immunosorbent assay system as described previously using the following antibodies: A␤40, MM27 33.1.1 capture, MM32 13.1.1 for detection; A␤42, MM27 33.1.1 capture, MM26 4.1.3 for detection (28) .
PKC Assay-PKC activity was measured by monitoring the phosphorylation of a PKC substrate peptide (QKRPSQRSKYL) using a PKC assay kit (Upstate Biotechnology, Lake Placid, NY). Lysates from brain or cortical neurons were harvested in PKC lysis buffer (150 mM phosphate-buffered saline (pH 7.4), 50 mM Tris HCl, 1% Nonidet P-40, 1 mM EDTA, plus 0.02 V protease and phosphatase inhibitor mixtures (Sigma)). Reactions were carried out in a 50-l volume at 30°C for 10 min in the presence of 20 mM MOPS (pH 7.2), 1 mM CaCl 2 , 25 mM ␤-glycerolphosphate, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 0.5 mg/ml phosphatidylserine, 0.5 mg/ml diacylglycerol, and 30 -100 g of sample. 10 l of an Mg 2ϩ /ATP mixture (75 mM magnesium chloride, 500 M ATP, 1-2 Ci of [ 32 P]ATP (3000 Ci/mmol)) was added to start the reaction. Twenty microliters of reaction mixture were spotted onto a 1-cm square of phosphocellulose P-81 paper at the end of the incubation period. The squares were washed five times with 0.75% phosphoric acid and once in acetone and counted for radioactivity. Samples containing no substrates were included in every experiment to determine basal levels of radioactivity, and the basal radioactivity was subtracted from the experimental counts.
Statistics-All results are presented as mean Ϯ S.E. When analysis of variance showed significant differences, pairwise comparisons between the means are analyzed by Newman-Keuls post-hoc testing. IC 50 values were calculated using the Prism program (GraphPad).
RESULTS
Production of Antibodies to CYP46A1-The ability of oxysterols to modulate APP processing suggests that their pattern of expression in the brain in AD could influence production of A␤. To explore this issue, we used immunochemistry to analyze the expression patterns of CYP46A1 and CYP27A1, which produce 24-and 27-OHC, respectively. We used three different antibodies. Antibodies 3046 and 3047 were generated against amino acids 226 -242 of human CYP46A1. Both antibodies identified CYP46A1 by immunoblotting (Fig. 1, A and B ). Antibodies 3046 and 3047 both recognized the 70-kDa band characteristic of CYP46A1. Preadsorption of both antibodies with the immunizing peptide eliminated all reactivity (Fig. 1D) . A third antibody, which was produced against amino acids 254 -270 of murine CYP46A1, gave a similar banding pattern (Fig. 1C) (5) .
Immunocytochemistry of CYP46A1 and Expression in Neurons, Astrocytes, and Senile Plaques-Next, we examined the distributions of CYP46A1 and CYP27A1 in human frontal cortex from donors without neurological disease. Antibody 3047 gave the least background staining. CYP46A1 expression was detected in pyramidal neurons ( Fig. 2A) as well as in occasional astrocytes (Fig. 2B) . No staining was observed with preimmune serum (Fig. 2D) . The relative amount of expression in astro-cytes and neurons did not show a correlation with post-mortem interval, sex, or age, although a larger sample size would be required to obtain definitive statistical information on this question. Staining with the anti-CYP46A1 antibody also showed reactivity in neurons and astrocytes in frontal cortex tissue from an AD brain, with more neurons evident in tissue from neurologically normal samples (Fig. 2E) . The striking feature of CYP46A1 staining in the Alzheimer brain tissue was the presence of CYP46A1 among neuritic plaques (Fig. 2C) . Staining of neurons and astrocytes in AD cortex was similar to that seen in normal cortex, although the number of neurons expressing CYP46A1 was decreased, possibly because of disease-related neuronal loss (Fig. 2E) . Preadsorption removed staining of CYP46A1 in neurons, astrocytes, and neuritic plaques (data not shown). To determine whether CYP46A1 staining localized to the amyloid core or the neuritic periphery, we performed double staining with thioflavine T (Fig. 3) . Double staining with thioflavine T and anti-CYP46A1 antibody 3047 showed that CYP46A1 reactivity was present in over 90% of the plaques identifiable by thioflavine T (Fig. 3) . The CYP46A1 reactivity was present in the periphery of neuritic plaques but did not co-localize with the amyloid core, suggesting that the CYP46A1 was not directly associated with compact, aggregated A␤ (Fig. 3) . The peripheral staining around neuritic plaques was consistent with staining in degenerating neurites. In contrast to the strong concordance between thioflavine staining and CYP46A1 staining, we did not observe CYP46A1 staining in any tangles that were thioflavine-positive (data not shown). A similar pattern of reactivity was observed for anti-CYP46A1 antibody 3046 (data not shown).
Next, we examined the pattern of CYP27A1 expression. The protein CYP27A1 was analyzed using an anti-CYP27A1 antibody recognizing amino acids 15-28 of mature CYP27A1, similar to one described previously by Cali and Russell (26) . In the normal cortex, CYP27A1 was present in many neurons where it showed strong reactivity in both the soma and proximal dendrites (Fig. 4A) . Little staining of CYP27A1 was observed in the white matter of normal brain (Fig. 4B) . The pattern of CYP27A1 staining in the AD brain differed from that in normal brain. Neuronal staining with anti-CYP27A1 antibody was greatly reduced (Fig. 4, C and E) . In contrast, there was a large increase of staining in the white matter of the AD brain (Fig. 4,  D and E) . The CYP27A1 reactivity present in the white matter occurred in the soma of small round cells, the morphology that is classic for oligodendrocytes (Fig. 4D) . In the AD brain, quantification showed a 66% (p Ͻ 0.05) reduction in the number of cortical neurons identified per high power field and a 4.6-fold (p Ͻ 0.01) increase in the number of oligodendrocytes identified per high power field (Fig. 4E) . The staining did not show a correlation with post-mortem interval, sex, or age, although a larger sample size would be required to obtain definitive statistical information on this question.
Quantification of CYP46A1 Levels in AD and Normal Brains-Immunocytochemical studies show that CYP46A1 and CYP27A1 proteins are present in multiple cell types in the AD and normal brain. To understand how the complex changes in expression affect the total expression of each protein, we performed immunoblots on cortical tissue from normal and AD brain. The CYP46A1 reactivity was apparent as a band at 70 kDa (Fig. 5A, arrow) . There was a large variation in the total expression of CYP46A1 among the brains. Although quantification of band intensities showed a modest increase in staining in the AD brain, the increase was not statistically significant (normalized OD: control, 0.17 Ϯ 0.15; AD, 0.34 Ϯ 0.20; n ϭ 7 each, p ϭ 0.094). The CYP27A1 reactivity was apparent as a band at 47 kDa (Fig. 5B, arrow) . CYP27A1 band intensity also showed variation among subjects, which resulted in no significant change in band intensity in AD brain samples (normalized OD: control, 0.35 Ϯ 0.21; AD, 0.21 Ϯ 0.11; n ϭ 7 each, p ϭ 0.13). The absence of disease-related differences in total CYP46A1 and CYP27A1 detected by immunoblot might occur because the decreased neuronal staining balances the increased staining in neuritic plaques (CYP46A1) or oligodendrocytes (CYP27A1).
24-OHC Inhibits APP Processing in Cortical Neurons Grown in Primary
Cultures-Recent studies show that the synthetic oxysterol 22-OHC inhibits A␤ secretion in cell lines, but the modulation of APP processing by the natural oxysterols 24- and   FIG. 3. CYP46A1 is located in and around the amyloid core of neuritic plaques. A, immunocytochemical staining of CYP46A1 (red) in the frontal cortex of Alzheimer tissue identifies neuritic plaques. B, thioflavine T (green) staining identifies neuritic plaques and exhibits intense reactivity in the amyloid core. C, merging panels A and B shows that CYP46A1 (red) reactivity is located around the amyloid core (green), suggesting that the enzyme is present in the neuritic periphery of the plaque. Bar, 30 m.
FIG. 4. Immunocytochemical staining of CYP27A1 in normal and AD frontal cortex.
A, staining of pyramidal neurons in gray matter in the frontal cortex from a neurologically normal specimen. Inset shows enlargement of a neuron (arrow). B, staining of white matter in a frontal cortex from a neurologically normal specimen. No prominent structures are observed. C, staining of pyramidal neurons in gray matter in a frontal cortex from an Alzheimer's disease specimen. Neuronal staining is less evident. D, staining of white matter in a frontal cortex from a neurologically normal specimen. Abundant reactivity with a pattern resembling that of oligodendrocytes is observed. Inset shows enlargement of an oligodendrocyte (arrow). E, counting of neurons and oligodendrocytes expressing CYP27A1 in an AD and a normal (Nml) brain. Significant disease-related changes are observed (counts represent four high power fields per brain from seven AD and seven normal brains, p Ͻ 0.05). Bar, 50 m.
27-OHC has yet to be investigated (19, 20) . In addition, modulation of APP processing by oxysterols in primary cultures of neurons also has not been investigated. To allow detection of A␤, cortical neurons were infected with adenovirus, driving the expression of human APP (23) . Two days later, the neurons were treated with 10 M 24-OHC for up to 24 h to determine whether oxysterols exerted rapid or delayed actions on A␤ or APP secretion. At this point, medium was collected for A␤ and APP analysis. We observed that 24-OHC inhibited both A␤ secretion and PMA-stimulated APP secretion (Fig. 6, A and B) . 24-OHC showed slightly stronger inhibition of A␤ and APP secretion after 24 h than after 6 h (Fig. 6A) . By 24 h, 24-OHC inhibited A␤ secretion by up to 68.5 Ϯ 1.6% (p Ͻ 0.001) and APP secretion by over 65% (at 6 h, 68.3 Ϯ 14.9% inhibition, p Ͻ 0.05; at 24 h, 87.1 Ϯ 10.4 inhibition, p Ͻ 0.005) (Fig. 6, A and  B) . No changes were observed in steady state levels of cellular APP, although the levels of ␣-C-terminal fragments were decreased in the presence of 24-OHC, suggesting that the changes in APP processing are the result of decreased cleavage of APP by secretases (Fig. 6C) . Next we examined the dose-response relationship of 24-OHC after 24 h treatment. 24-OHC inhibited secretion of A␤40 and A␤42, with an IC 50 of ϳ7 nM, based on a plateau for inhibition at 40% control values (Fig. 6, D and E) . 24-OHC also prevented PKC from stimulating APP secretion, exhibiting an IC 50 for the inhibition of APP secretion similar to that observed for the inhibition of A␤ secretion (Fig. 6F) .
To determine whether the changes in APP processing correlated with LXR activity, we analyzed the expression of ABCA1, which is induced by LXR activity. Primary neurons were treated with 24-OHC as described above, and then ABCA1 expression in the lysates was determined by immunoblot. Expression of ABCA1 was stimulated by treatment with 1 M 24-OHC, consistent with LXR activation (Fig. 6G) . Finally, we investigated whether 24-OHC was causing toxicity in the neuronal cultures, because toxicity could reduce A␤ secretion. Analysis of toxicity by an assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide showed no evidence of neurotoxicity over 24 h of OHC treatment at doses below 5 M 24-OHC (data not shown). These data indicate that 24-OHC inhibits both A␤ and APP secretion and that the inhibition is accompanied by LXR activation.
27-OHC Inhibits A␤ and APPs Secretion-Next we examined the effects of 27-OHC on APP processing. We observed that 27-OHC also inhibited APP processing, although with lower potency. Cortical neurons grown in primary culture were exposed for 24 h to 1-15 M 27-OHC. The medium and cellular lysates were then collected, and APP processing was examined. 27-OHC inhibited secretion of A␤40 and A␤42 with an IC 50 of ϳ2 M, based on a plateau for inhibition at 62% of control values (Figs. 6, A and D, and 7A ). 27-OHC also inhibited PKC stimulated APP secretion (Fig. 7C) . Immunoblots of the lysates with anti-ABCA1 antibody indicated that the induction of ABCA1 paralleled the inhibition of APP processing (Fig. 7D) . This suggests that the inhibition of A␤ by 27-OHC was less potent than that by 24-OHC but is consistent with a mechanism involving LXR. We did not observe any neurotoxicity with 27-OHC using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (data not shown).
Finally, to compare our results with previous studies, we examined whether the LXR agonist TO901317 affects APP processing. Cortical neurons grown in primary culture were exposed for 24 h to 1 M TO901317. The medium was collected, and levels of A␤40 were measured. Treatment with 1 M TO901317 reduced levels of A␤40 by 39 Ϯ 18% (p Ͻ 0.002).
24-OHC Inhibits Protein Kinase C Activity-Because 24-OHC showed the most pronounced inhibition of APP secretion under conditions of PKC activation, we examined whether oxysterols inhibit PKC activity. Primary cortical neurons were treated with varying doses of 24-OHC for 24 h and then with PMA for 15 min, neurons were harvested, and PKC activity was measured. 24-OHC inhibited PKC activity at doses similar to those that inhibit APP secretion (Fig. 8A) . To determine whether 24-OHC acts directly or indirectly on PKC, we examined the effects of 24-OHC on PKC activity in neuronal and brain lysates. When the 24-OHC was applied to the lysates rather than intact cells, 24-OHC failed to inhibit PKC activity (Fig. 8B) . These results suggested that 24-OHC inhibits PKC through an indirect mechanism and would be consistent with inhibition secondary to activation of LXR. Inhibition of PKC by 24-OHC could provide a mechanism by which 24-OHC inhibits PKC-stimulated APP secretion in neurons. DISCUSSION We examined the distribution of CYP46A1 and CYP27A1 in normal and AD brains and determined how oxysterols affect APP processing in neurons. Expression of CYP46A1 and CYP27A1 in the neuronal soma is reduced in the AD brain, with CYP46A1 showing a selective accumulation around neuritic plaques and CYP27A1 a selective increase in expression in white matter. Analysis of APP processing showed that 24-and 27-OHC inhibited A␤ secretion, and PMA stimulated APP secretion but did not affect steady state levels of cellular APP. Inhibition by 24-OHC was 1000-fold more potent than inhibition by 27-OHC. Inhibition of APP processing was not explained by neurotoxicity because inhibition was apparent in the low nanomolar range, which was far lower than doses of 24-OHC that are reported by others to cause toxicity (29 -31). 24-OHC inhibits PKC activity in intact cells but not in cell lysates, suggesting a mechanism for oxysterol-mediated inhibition of APP secretion. Taken together, the results point to roles for oxysterols in APP processing and the pathophysiology of AD.
Previous studies have examined the actions of synthetic oxysterols. Both Koldmova et. al. (19) and Sun et. al. (20) observed that the LXR agonist 22-OHC inhibits A␤ secretion in neuronal cell lines, and Sun et. al. observed that the LXR agonist TO901317 also inhibited A␤ secretion. Regulation of APP processing by oxysterols might be sensitive to conditions or to cell lines because Fukumoto et. al. (25) observed that 22-OHC and TO90317 increase secretion of A␤42 but do not affect secretion of A␤40 or APP, despite the clear induction of ABCA1. Neuronal cell lines are advantageous for studying APP processing because many are of human origin, and they can be stably transfected with APP to boost expression. Transformed neuronal cell lines, however, often display less pronounced neuronal physiology than primary cultures of neurons from the brain; for instance, they display fewer synapses, no action potentials, no dendrites, and lower levels of many neuronal proteins, such as tau or neurotransmitter receptors (e.g. N-methyl-D-aspartate receptors). These limitations prompted us to examine the regulation of APP processing in primary cortical neurons. We observed potent inhibition of the A␤ secretion by oxysterols and TO901317 in the primary neuronal cultures. The slow time course of action of oxysterols combined with previous data by Koldamova et. al. (19) and Sun et. al. (20) suggest that oxysterols inhibit APP processing in neurons through a mechanism mediated by LXR. The presence of retinoic acid in the B27 supplement required to maintain the neurons would enable activation of the LXR/RXR system. Determining how LXR and RXR regulate APP processing requires further work. Both ␤-and ␥-secretases are located in cholesterol-rich domains in the cell, and ␤-secretase activity appears to be particularly sensitive to cholesterol levels (10, 14, 15, 27, 32) . Activation of the LXR/RXR system is known to increase ABCA1 levels (20) . Because ABCA1 secretes cholesterol, elevated ABCA1 might reduce cellular cholesterol and in turn reduce ␤-secretase activity.
The observation that oxysterols inhibit PKC represents a mode of action of oxysterols that has not been documented previously. The ability of 24-OHC to inhibit PKC-stimulated APP secretion suggested that oxysterols might inhibit the PKC pathway, which led to the studies of putative regulation of PKC by oxysterols. Consistent with this hypothesis, our studies showed that 24-OHC inhibits PKC activity in intact neurons. The similarity of the IC 50 for inhibition of APP secretion and inhibition of PKC activity by 24-OHC raises the possibility that inhibition of PKC mediates the inhibition of PKC-stimulated APP secretion. Definitive proof that oxysterol-mediated inhibition of APP processing occurs via inhibition of PKC requires further studies to identify which PKC isozyme is sensitive to oxysterols and whether modulation of PKC levels (by overexpression or knock-down) modifies the oxysterol-mediated regulation of APP processing. Inhibition of PKC by cholesterol metabolites has been observed previously in the literature. Cholesterol sulfate was shown to directly stimulate PKC (33) . Cholesterol metabolites also are known to regulate other signal transduction cascades. For instance, ursodeoxycholic acid inhibits apoptosis at the level of the mitochondria (34, 35) . Cholesterol sulfate and ursodeoxycholic acid appear to act directly on the signal transduction molecules, but 24-OHC was unable to inhibit PKC activity in neuronal lysates. The inability of 24-OHC to inhibit PKC in cell lysates and the similarity between the dose-response profile for inhibition of PKC and inhibition of APP processing suggest that the mechanism of PKC inhibition might be via the LXR receptor, which is a known target of oxysterols (4, 20, 36) .
The ability of oxysterols to regulate APP processing suggests that the pattern of oxysterol production could have a significant impact on the pathophysiology of AD. Levels of oxysterols in blood increase in AD and other cases of neurodegeneration (6 -8, 21) . Studies investigating 24-OHC production in the brain, however, present a more complicated scenario. A recent study (37) suggests that total production of 24-OHC actually decreases slightly in AD, whereas production of 27-OHC increases. An earlier study examined the expression of CYP46A1 in AD and noted its presence in neuritic plaques (38) . To complement and extend this study, we compared the expression patterns of CYP46A1 with CYP27A1 in the Alzheimer brain. Immunoblotting whole brain homogenates revealed variable expression of both CYP46A1 and CYP27A1 among subjects and no clear disease-related trend. One reason for the absence of a clear disease-related trend in CYP46A1 or CYP27A1 expression could be the complex changes in the pattern of expression in the AD brain. At the cellular level, CYP46A1 was expressed in neurons and astrocytes in normal brain. In AD, the numbers of astrocytes expressing CYP46A1 increased, and the number of neurons expressing CYP46A1 decreased. In addition, we observed prominent staining of CYP46A1 in and around neuritic plaques. The presence of CYP46A1 in neuritic plaques, neurons, and astrocytes also was observed previously in a study (38) that reported the presence of CYP46A1 in the amyloid core. Our data confirmed the neuronal and astrocytic expression pattern but detected CYP46A1 in the neuritic periphery of plaques, rather than the amyloid core. Restriction of CYP46A1 to the neuritic periphery as observed here might be more consistent with its biology, because CYP46A1 is a membrane-bound protein of the endoplasmic reticulum and has not been reported to be secreted. The induction of CYP46A1 around neuritic plaques suggests that there is increased production of 24-OHC in the degenerating neurites surrounding neuritic plaques. Increased oxysterol synthesis would be expected to decrease A␤ production around neuritic plaques as neurons degenerate.
The expression pattern of CYP27A1 contrasted with that of CYP46A1. CYP27A1 was present in neurons, where it was particularly prominent in the cell bodies and proximal dendrites. CYP27A1 also was present in astrocytes and oligodendrocytes. In AD, expression of CYP27A1 in neurons decreased, perhaps reflecting the loss of neurons in AD, but no CYP27A1 expression was observed around neuritic plaques. The absence of CYP27A1 in neurites around senile plaques identifies an intriguing difference in the regulation of these two enzymes. CYP46A1 expression might be more closely linked with synaptic plasticity than CYP27A1, which would be consistent with the brain selective expression pattern of CYP46A1. The reduction of neuronal CYP27A1 staining contrasts with increased staining of oligodendrocytes in the white matter. This change possibly reflects the reduced need of myelin in the AD brain as neurons degenerate. The increased CYP27A1 staining in white matter compensated for the decreased neuronal expression of CYP27A1 in AD. Perhaps because of this inverse change, total levels of CYP27A1 in the brain were not significantly altered in the AD cortex, although disease-specific changes in particular regions are evident.
The retraction of synaptic trees associated with neurodegeneration in AD demands redistribution of cholesterol. The expression of CYP46A1 in dystrophic neurites around amyloid plaques appears to be part of this degenerative process, although how CYP46A1 contributes to neuronal degeneration remains to be determined. A mouse lacking Cyp46A1 was recently generated, and the preliminary studies failed to demonstrate effects of Cyp46A1 deletion on neuronal responses to injury (39) . Neurodegeneration can also be considered to be analogous to large scale synaptic plasticity, and it is possible that production of Cyp46A1 contributes to the plasticity. It will be interesting to observe how the expression of CYP46A1 and CYP27A1 changes in other models of synaptic plasticity, such as neuronal development, hippocampal long term potentiation, and diseases such as frontotemporal dementia or NieimannPick C disorder that show neurofibrillary tangles without amyloid plaques (40, 41) .
